Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
7
×
fda
7
×
life sciences
national blog main
boston blog main
boston top stories
clinical trials
national top stories
boston
new york blog main
new york top stories
san diego blog main
san diego top stories
alnylam pharmaceuticals
patisiran
san francisco blog main
san francisco top stories
akcea therapeutics
biotech
hereditary transthyretin amyloidosis
inotersen
onpattro
rna interference
tafamidis
acute hepatic porphyrias
akin akinc
allopregnanolone
aminolevulinic acid
barry greene
blueprint medicines
boston university
boulder/denver blog main
boulder/denver top stories
brexanolone
cancer
cannabidiol
companion diagnostic
dan ollendorf
detroit blog main
detroit top stories
What
fda
medicine
7
×
drug
ago
alnylam
approved
rna
cells
interference
new
oks
pharmaceuticals
rnai
second
time
uses
weeks
approval
approve
approves
awaits
battle
biological
brexanolone
cancer
cannabis
cleared
clinical
company
cosmeceutical
crossed
data
decades
decision
deeper
depression
derivative
devastating
diego’s
discovered
Language
Current search:
fda
×
medicine
×
drugs
×
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
@xconomy.com
6 years ago
Histogen Treatment for Female Hair Loss Cleared for Clinical Testing